Scarica l'app Stockscreener
1.5699
9.44%
0.1399
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Precedente Chiudi:
$1.43
Aprire:
$1.46
Volume 24 ore:
871.49K
Relative Volume:
0.34
Capitalizzazione di mercato:
$118.04M
Reddito:
$78.12M
Utile/perdita netta:
$-153.22M
Rapporto P/E:
-0.7658
EPS:
-2.05
Flusso di cassa netto:
$-136.90M
1 W Prestazione:
+23.23%
1M Prestazione:
-26.87%
6M Prestazione:
-65.90%
1 anno Prestazione:
-82.78%
Intervallo 1D:
$1.45
$1.57
Intervallo di 1 settimana:
$1.26
$1.57
Portata 52W:
$1.1601
$11.58
Editas Medicine Inc Stock (EDIT) Company Profile
Nome
Editas Medicine Inc
Settore
Industria
Telefono
617-401-9000
Indirizzo
11 HURLEY ST., CAMBRIDGE, MA
Confronta EDIT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
1.569 | 118.04M | 78.12M | -153.22M | -136.90M | -2.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.00 | 103.65B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
729.98 | 78.71B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
659.42 | 38.59B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.25 | 30.07B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
126.45 | 28.82B | 3.30B | -501.07M | 1.03B | -2.1146 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Downgrade | Stifel | Buy → Hold |
| 2024-12-13 | Downgrade | Truist | Buy → Hold |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-11-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-05-09 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-10-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Aggiornamento | Stifel | Hold → Buy |
| 2023-06-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Iniziato | Citigroup | Neutral |
| 2022-12-06 | Ripresa | Credit Suisse | Neutral |
| 2022-11-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Iniziato | BofA Securities | Neutral |
| 2021-10-19 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-09-24 | Iniziato | Stifel | Hold |
| 2021-09-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Aggiornamento | Truist | Hold → Buy |
| 2021-08-05 | Aggiornamento | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Iniziato | Goldman | Sell |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Downgrade | Truist | Buy → Hold |
| 2021-01-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Iniziato | Robert W. Baird | Underperform |
| 2020-06-18 | Ripresa | SunTrust | Buy |
| 2020-02-21 | Iniziato | Wells Fargo | Equal Weight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-10 | Iniziato | Guggenheim | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Outperform |
| 2018-05-15 | Reiterato | Chardan Capital Markets | Buy |
| 2018-02-13 | Iniziato | CLSA | Underperform |
| 2018-01-23 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-07-14 | Iniziato | SunTrust | Hold |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-06-02 | Iniziato | Jefferies | Hold |
| 2016-02-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-29 | Iniziato | JP Morgan | Neutral |
| 2016-02-29 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Editas Medicine Inc Borsa (EDIT) Ultime notizie
Editas Medicine To Present At The 43rd Annual J.P. Morgan Healthcare Conference - Barchart
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Editas Medicine CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Top 5 CRISPR Companies To Invest In (January 2025) - Securities.io
Short Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Increases By 5.4% - MarketBeat
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
State Street Corp Cuts Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $7.00 Average PT from Brokerages - MarketBeat
Editas Medicine (STU:8EM) Cyclically Adjusted FCF per Share : €-1.69 (As of Sep. 2024) - GuruFocus.com
Editas Medicine stock plunges to 52-week low of $1.27 - Investing.com
Cambridge company is laying of 180 people, 65% of its workforce - MSN
Editas Medicine's SWOT analysis: gene editing firm pivots strategy amid stock uncertainty - Investing.com
Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program - MSN
JP Morgan Downgrades Editas Medicine (EDIT) - MSN
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce - MSN
EDIT Stock Falls On Decision To End Reni-Cel Studies, Cut Workforce - Barchart
Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $5.00 at Evercore ISI - MarketBeat
JPMorgan Chase & Co. Downgrades Editas Medicine (NASDAQ:EDIT) to Underweight - MarketBeat
Five things: Editas cuts, CVS shares, Moderna's name and the best birthday gift ever - The Business Journals
Brokerages downgrade gene editing company Editas to 'hold', shares slump 23% - MSN
Editas cut to equal weight by Wells Fargo over reni-cel positioning - MSN
Chardan Capital Downgrades Editas Medicine (EDIT) - MSN
Barclays Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $3.00 - MarketBeat
Editas Medicine price target lowered to $8 from $10 at Baird - Yahoo Finance
Editas Medicine to reduce about 65% of its workforce over the next six months - ETHRWorld.com
Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts - GuruFocus.com
Truist cuts Editas Medicine stock to Hold, removes price target By Investing.com - Investing.com Canada
Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $4.00 at Royal Bank of Canada - MarketBeat
Editas Medicine (EDIT) PT Lowered to $5 at Evercore ISI - StreetInsider.com
Cambridge biotech company lays off more than half its employees - NBC Boston
Gene-editing pioneer Editas lays off more than half its employees - The Business Journals
Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program (NASDAQ:EDIT) - Seeking Alpha
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Editas Medicine's (EDIT) "Neutral" Rating Reaffirmed at Chardan Capital - MarketBeat
Editas Medicine (NASDAQ:EDIT) Price Target Cut to $8.00 by Analysts at Robert W. Baird - MarketBeat
Editas to lay off staff after search for sickle cell partner comes up empty - Yahoo Finance
Editas Medicine (NASDAQ:EDIT) Downgraded to Hold Rating by Truist Financial - MarketBeat
Chardan Capital Markets Downgrades Editas Medicine (EDIT) to Neutral - StreetInsider.com
Editas Medicine (NASDAQ:EDIT) Cut to "Hold" at Stifel Nicolaus - MarketBeat
Editas Axes 60% of Staff, Sickle Cell Therapy After Failing to Find Partner - BioSpace
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 - Benzinga
Editas axes two-thirds of its staff, including its CMO - pharmaphorum
Editas Medicine stock plunges to 52-week low at $1.89 By Investing.com - Investing.com Canada
Editas stock downgraded to hold, price target slashed - Investing.com
Editas Medicine's SWOT analysis: gene editing firm's stock faces pivotal phase - Investing.com Nigeria
Editas Medicine, Inc. Announces Management Changes - Marketscreener.com
Editas shifts focus to in vivo CRISPR gene editing - Investing.com India
Editas to reduce about 65% of its workforce over the next six months - 1470 & 100.3 WMBD
Editas Medicine Announces Strategic Transition to in vivo - GlobeNewswire
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years - The Manila Times
Editas Medicine Pivots Gene Editing Strategy, Cutting 65% of Workforce - MarketWatch
Editas Medicine Inc Azioni (EDIT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.44%
2.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):